94 related articles for article (PubMed ID: 28683361)
1.
Lyczko M; Pruszynski M; Majkowska-Pilip A; Lyczko K; Was B; Meczynska-Wielgosz S; Kruszewski M; Szkliniarz K; Jastrzebski J; Stolarz A; Bilewicz A
Nucl Med Biol; 2017 Oct; 53():1-8. PubMed ID: 28683361
[TBL] [Abstract][Full Text] [Related]
2. Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.
Pruszyński M; Bilewicz A; Zalutsky MR
Bioconjug Chem; 2008 Apr; 19(4):958-65. PubMed ID: 18338858
[TBL] [Abstract][Full Text] [Related]
3. Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.
Pruszyński M; Łyczko M; Bilewicz A; Zalutsky MR
Nucl Med Biol; 2015 May; 42(5):439-445. PubMed ID: 25687450
[TBL] [Abstract][Full Text] [Related]
4. Application of Neurokinin-1 Receptor in Targeted Strategies for Glioma Treatment. Part I: Synthesis and Evaluation of Substance P Fragments Labeled with
Majkowska-Pilip A; Koźmiński P; Wawrzynowska A; Budlewski T; Kostkiewicz B; Gniazdowska E
Molecules; 2018 Oct; 23(10):. PubMed ID: 30301182
[TBL] [Abstract][Full Text] [Related]
5. Radioiodinated and astatinated NHC rhodium complexes: synthesis.
Rajerison H; Guérard F; Mougin-Degraef M; Bourgeois M; Da Silva I; Chérel M; Barbet J; Faivre-Chauvet A; Gestin JF
Nucl Med Biol; 2014 May; 41 Suppl():e23-9. PubMed ID: 24661351
[TBL] [Abstract][Full Text] [Related]
6. Nanozeolite bioconjugates labeled with
Piotrowska A; Męczyńska-Wielgosz S; Majkowska-Pilip A; Koźmiński P; Wójciuk G; Cędrowska E; Bruchertseifer F; Morgenstern A; Kruszewski M; Bilewicz A
Nucl Med Biol; 2017 Apr; 47():10-18. PubMed ID: 28043005
[TBL] [Abstract][Full Text] [Related]
7. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.
Kneifel S; Cordier D; Good S; Ionescu MC; Ghaffari A; Hofer S; Kretzschmar M; Tolnay M; Apostolidis C; Waser B; Arnold M; Mueller-Brand J; Maecke HR; Reubi JC; Merlo A
Clin Cancer Res; 2006 Jun; 12(12):3843-50. PubMed ID: 16778112
[TBL] [Abstract][Full Text] [Related]
8. 211AtCl@US-tube nanocapsules: a new concept in radiotherapeutic-agent design.
Hartman KB; Hamlin DK; Wilbur DS; Wilson LJ
Small; 2007 Sep; 3(9):1496-9. PubMed ID: 17668431
[No Abstract] [Full Text] [Related]
9. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for
Pozzi OR; Zalutsky MR
Nucl Med Biol; 2017 Mar; 46():43-49. PubMed ID: 28013121
[TBL] [Abstract][Full Text] [Related]
10. Preparation and first biological evaluation of novel Re-188/Tc-99m peptide conjugates with substance-P.
Smilkov K; Janevik E; Guerrini R; Pasquali M; Boschi A; Uccelli L; Di Domenico G; Duatti A
Appl Radiat Isot; 2014 Sep; 92():25-31. PubMed ID: 24973465
[TBL] [Abstract][Full Text] [Related]
11. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy.
Ogawa K; Mizuno Y; Washiyama K; Shiba K; Takahashi N; Kozaka T; Watanabe S; Shinohara A; Odani A
Nucl Med Biol; 2015 Nov; 42(11):875-9. PubMed ID: 26235266
[TBL] [Abstract][Full Text] [Related]
14. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
Larsen RH; Akabani G; Welsh P; Zalutsky MR
Radiat Res; 1998 Feb; 149(2):155-62. PubMed ID: 9457895
[TBL] [Abstract][Full Text] [Related]
15. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
16. Targeted Radiolabeled Compounds in Glioma Therapy.
Cordier D; Krolicki L; Morgenstern A; Merlo A
Semin Nucl Med; 2016 May; 46(3):243-9. PubMed ID: 27067505
[TBL] [Abstract][Full Text] [Related]
17. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.
Pozzi OR; Zalutsky MR
J Nucl Med; 2007 Jul; 48(7):1190-6. PubMed ID: 17574991
[TBL] [Abstract][Full Text] [Related]
18. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
Shankar S; Vaidyanathan G; Kuan CT; Bigner DD; Zalutsky MR
Nucl Med Biol; 2006 Jan; 33(1):101-10. PubMed ID: 16459265
[TBL] [Abstract][Full Text] [Related]
19. Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.
Talanov VS; Yordanov AT; Garmestani K; Milenic DE; Arora HC; Plascjak PS; Eckelman WC; Waldmann TA; Brechbiel MW
Nucl Med Biol; 2004 Nov; 31(8):1061-71. PubMed ID: 15607488
[TBL] [Abstract][Full Text] [Related]
20. An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals.
Cai H; Li Z; Huang CW; Park R; Shahinian AH; Conti PS
Nucl Med Biol; 2010 Jan; 37(1):57-65. PubMed ID: 20122669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
